The requested figure was not found.
Type I IFN has been demonstrated to have major regulatory effects on the outcome of bacterial infections. To assess the effects of exogenously induced type I IFN on the outcome of Mycobacterium tuberculosis infection, we treated pathogen-exposed mice intranasally with polyinosinic-polycytidylic acid condensed with poly-l-lysine and carboxymethylcellulose (Poly-ICLC), an agent designed to stimulate prolonged, high-level production of type I IFN. Drug-treated, M. tuberculosis–infected WT mice, but not mice lacking IFN-αβ receptor 1 (IFNαβR; also known as IFNAR1), displayed marked elevations in lung bacillary loads, accompanied by widespread pulmonary necrosis without detectable impairment of Th1 effector function. Importantly, lungs from Poly-ICLC–treated M. tuberculosis–infected mice exhibited a striking increase in CD11b+F4/80+Gr1int cells that displayed decreased MHC II expression and enhanced bacterial levels relative to the same subset of cells purified from infected, untreated controls. Moreover, both the Poly-ICLC–triggered pulmonary recruitment of the CD11b+F4/80+Gr1int population and the accompanying exacerbation of infection correlated with type I IFN–induced upregulation of the chemokine-encoding gene Ccl2 and were dependent on host expression of the chemokine receptor CCR2. The above findings suggest that Poly-ICLC treatment can detrimentally affect the outcome of M. tuberculosis infection, by promoting the accumulation of a permissive myeloid population in the lung. In addition, these data suggest that agents that stimulate type I IFN should be used with caution in patients exposed to this pathogen.
Lis R.V. Antonelli, Antonio Gigliotti Rothfuchs, Ricardo Gonçalves, Ester Roffê, Allen W. Cheever, Andre Bafica, Andres M. Salazar, Carl G. Feng, Alan Sher
Title and authors | Publication | Year |
---|---|---|
Exposure to Mycobacterium remodels alveolar macrophages and the early innate response to Mycobacterium tuberculosis infection
Mai D, Jahn A, Murray T, Morikubo M, Lim PN, Cervantes MM, Pham LK, Nemeth J, Urdahl K, Diercks AH, Aderem A, Rothchild AC |
PLoS pathogens | 2024 |
Aromatic amino acid metabolites alter interferon signaling and influenza pathogenesis
Anand G, Clark-Dinovo C, Perry AM, Goodwin VM, St. Raymond E, Sakleshpur S, Steed AL |
Frontiers in Molecular Biosciences | 2024 |
Zebrafish tsc1 and cxcl12a increase susceptibility to mycobacterial infection
Wright K, Han DJ, Song R, de Silva K, Plain KM, Purdie AC, Shepherd A, Chin M, Hortle E, Wong JJ, Britton WJ, Oehlers SH |
Life science alliance | 2024 |
A protective role for type I interferon signaling following infection with Mycobacterium tuberculosis carrying the rifampicin drug resistance-conferring RpoB mutation H445Y
Bobba S, Chauhan KS, Akter S, Das S, Mittal E, Mathema B, Philips JA, Khader SA |
PLoS pathogens | 2024 |
Mycobacterial CpsA activates type I IFN signaling in macrophages via cGAS-mediated pathway
Ding Y, Tong J, Luo G, Sun R, Bei C, Feng Z, Meng L, Wang F, Zhou J, Chen Z, Li D, Fan Y, Song S, Wang D, Feng CG, Liu H, Chen Q, Yan B, Gao Q |
iScience | 2024 |
Antimycobacterial and healing effects of Pranlukast against MTB infection and pathogenesis in a preclinical mouse model of tuberculosis
Rajmani RS, Surolia A |
Frontiers in immunology | 2024 |
Increased serum interferon activity in sarcoidosis compared to that in tuberculosis: Implication for diagnosis?
Schrijver B, Göpfert J, La Distia Nora R, Putera I, Nagtzaam NMAN, Smits Te Nijenhuis MAW, van Rijswijk ALCT, Ten Berge JCEM, van Laar JAM, van Hagen PM, Dik WA |
Heliyon | 2024 |
Intranasal vaccination with engineered BCG expressing CCL2 induces a stronger immune barrier against Mycobacterium tuberculosis than BCG.
Guo S, Ouyang J, Hu Z, Cao T, Huang C, Mou J, Gu X, Liu J |
Molecular therapy : the journal of the American Society of Gene Therapy | 2024 |
APOE Protects Against Severe Infection with Mycobacterium tuberculosis by Restraining Production of Neutrophil Extracellular Traps
Liu D, Mai D, Jahn AN, Murray TA, Aitchison JD, Gern BH, Urdahl KB, Aderem A, Diercks AH, Gold ES |
bioRxiv | 2024 |
Unmasking the hidden impact of viruses on tuberculosis risk
Darboe F, Reijneveld JF, Maison DP, Martinez L, Suliman S |
Trends in immunology | 2024 |